Daiwa Securities Group Inc. Has $331,000 Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Daiwa Securities Group Inc. decreased its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,630 shares of the biotechnology company’s stock after selling 124 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Ascendis Pharma A/S were worth $331,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Westfield Capital Management Co. LP raised its position in shares of Ascendis Pharma A/S by 4.7% during the third quarter. Westfield Capital Management Co. LP now owns 3,802,177 shares of the biotechnology company’s stock worth $356,036,000 after purchasing an additional 170,465 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S by 16.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,264,470 shares of the biotechnology company’s stock worth $118,405,000 after purchasing an additional 176,948 shares during the period. TimesSquare Capital Management LLC raised its position in shares of Ascendis Pharma A/S by 9.8% during the third quarter. TimesSquare Capital Management LLC now owns 842,801 shares of the biotechnology company’s stock worth $78,920,000 after purchasing an additional 75,374 shares during the period. Invesco Ltd. raised its position in shares of Ascendis Pharma A/S by 9.3% during the third quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock worth $62,938,000 after purchasing an additional 57,413 shares during the period. Finally, Brown Advisory Inc. raised its position in shares of Ascendis Pharma A/S by 2.7% during the third quarter. Brown Advisory Inc. now owns 510,109 shares of the biotechnology company’s stock worth $47,767,000 after purchasing an additional 13,227 shares during the period.

Ascendis Pharma A/S Stock Down 0.8 %

ASND stock opened at $135.90 on Friday. The business has a 50 day moving average price of $148.88 and a two-hundred day moving average price of $125.68. The company has a market cap of $7.91 billion, a price-to-earnings ratio of -14.69 and a beta of 0.50. Ascendis Pharma A/S has a twelve month low of $66.03 and a twelve month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The firm had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -4.15 EPS for the current fiscal year.

Analyst Ratings Changes

ASND has been the topic of a number of research analyst reports. Citigroup raised their price target on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. Wells Fargo & Company lifted their target price on Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Wedbush lifted their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, April 18th. Finally, JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.